KPTI
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
Karyopharm Therapeutics Inc. (KPTI) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | C+ (2.8) | B (3.4) | C+ (2.5) | F (0.0) | C (2.3) |
| 2026-11-06 | B- (3.0) | C+ (2.7) | B (3.4) | F (0.3) | F (0.0) | C- (1.9) |
| 2026-10-30 | B- (3.0) | C+ (2.6) | B+ (3.5) | F (0.7) | C+ (2.7) | C (2.5) |
| 2026-10-23 | B- (3.0) | C+ (2.6) | B (3.5) | F (0.4) | F (0.0) | C- (1.9) |
| 2026-10-16 | B- (3.0) | C+ (2.6) | B (3.5) | F (0.4) | F (0.0) | C- (1.9) |